Company type | Società per Azioni, (S.p.A.) (something like a Joint-Stock company) |
---|---|
Industry | Pharmaceuticals |
Founded | 1935 |
Headquarters | Parma , Italy |
Key people | Alberto Chiesi (President) Paolo Chiesi (Vice-president) Giuseppe Accogli(CEO) |
Revenue | €3 billion (2023) |
Number of employees | 6500 |
Website | www |
Chiesi Farmaceutici S.p.A. is an Italian family controlled[1][2] global pharmaceutical company based in Parma, Emilia-Romagna. Chiesi has 31 affiliates[3] in the world, nearly 6,500 total employees[4] and provides medicines to patients in 100 nations. Chiesi currently has revenues of 3 billion euros.[4] According to 2020 official data from the European Patent Office (EPO), Chiesi Group, with 42 patents filed, is confirmed as the first Italian Pharmaceutical Company and third among Italian Companies across all sectors for filing the highest number of patents.[5]
In June 2019, Chiesi became a certified B Corporation, thus choosing to adopt a new legal status under US and Italian law. This ensures Chiesi legal protection to pursue a business model placing social and environmental values on equal footing with profits.[6]
Following the acquisition, in 1999, of Huddersfield based Trinity Pharmaceuticals, Chiesi has also had a significant presence in Manchester, United Kingdom.[7]